Belzupacap sarotalocan

沙比帕克贝

Report date: 2025/06/12 16:52:28

NMEFirst In Class

Base Information

Drug NameBelzupacap sarotalocan

Drug Alias NameHPV virus-like nanoparticles bound to IR-700 (cancer/uveal melanoma), Aura Biosciences/NIHHPV-derived nanoparticles conjugated to infrared dye (cancer/uveal melanoma), Aura Biosciences/NIHBel-sarAU-011IR-700-VLP +[6]

ClassificationOther

Mechanisms of ActionReactive oxygen species stimulantsPhotosensitizersCell death stimulants

TargetsReactive oxygen species

Therapy Area/IndicationsUveal melanomaUrinary Bladder NeoplasmsEye Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumCanada +[14]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute Aura Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesAura Biosciences Inc

Inactive CompaniesN/A

Active IndicationsUveal melanomaUrinary Bladder NeoplasmsEye Neoplasms +[6]

Inactive IndicationsN/A

Other Information

ATC CodeN/A